64 related articles for article (PubMed ID: 18424917)
1. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies.
Bergado-Báez G; Gonzalez Suarez N; García LC; Pérez-Martínez D; Hernández-Fernández DR; Fundora-Barrios T; Rodríguez-Álvarez A; Díaz-Ordaz GD; Lindzen M; Yarden Y; Sánchez-Ramírez B
Front Oncol; 2022; 12():951267. PubMed ID: 36408164
[TBL] [Abstract][Full Text] [Related]
3. Bivalent EGFR-Targeting DARPin-MMAE Conjugates.
Karsten L; Janson N; Le Joncour V; Alam S; Müller B; Tanjore Ramanathan J; Laakkonen P; Sewald N; Müller KM
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269611
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Naidoo DB; Chuturgoon AA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
[TBL] [Abstract][Full Text] [Related]
5. Multimodal Bone Metastasis-associated Epidermal Growth Factor Receptor Imaging in an Orthotopic Rat Model.
Bäuerle T; Gupta S; Zheng S; Seyler L; Leporati A; Marosfoi M; Maschauer S; Prante O; Caravan P; Bogdanov A
Radiol Imaging Cancer; 2021 Jul; 3(4):e200069. PubMed ID: 34170199
[TBL] [Abstract][Full Text] [Related]
6. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity.
Ding X; Gu W; Zhong Y; Hao X; Liu J; Xia S; Luo L; Chen M; Zhang C
EBioMedicine; 2020 Oct; 60():102996. PubMed ID: 32950002
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR Agents: Current Status, Forecasts and Future Directions.
Kwapiszewski R; Pawlak SD; Adamkiewicz K
Target Oncol; 2016 Dec; 11(6):739-752. PubMed ID: 27515815
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers.
Simon N; FitzGerald D
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153091
[TBL] [Abstract][Full Text] [Related]
9. Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer.
Ko BK; Choi S; Cui LG; Lee YH; Hwang IS; Kim KT; Shim H; Lee JS
PLoS One; 2015; 10(7):e0134600. PubMed ID: 26225765
[TBL] [Abstract][Full Text] [Related]
10. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
11. High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface.
Rojas G; Tundidor Y; Infante YC
MAbs; 2014; 6(6):1368-76. PubMed ID: 25484050
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
13. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
[TBL] [Abstract][Full Text] [Related]
14. Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.
Tundidor Y; García-Hernández CP; Pupo A; Cabrera Infante Y; Rojas G
MAbs; 2014; 6(4):1013-25. PubMed ID: 24759767
[TBL] [Abstract][Full Text] [Related]
15. A simple contact mapping algorithm for identifying potential peptide mimetics in protein-protein interaction partners.
Krall A; Brunn J; Kankanala S; Peters MH
Proteins; 2014 Sep; 82(9):2253-62. PubMed ID: 24756879
[TBL] [Abstract][Full Text] [Related]
16. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
17. MR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model.
Shazeeb MS; Gupta S; Bogdanov A
Mol Imaging Biol; 2013 Dec; 15(6):675-84. PubMed ID: 23733229
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
19. Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation.
Chang KH; Kim MS; Hong GW; Seo MS; Shin YN; Kim SH
Immune Netw; 2012 Aug; 12(4):155-64. PubMed ID: 23091439
[TBL] [Abstract][Full Text] [Related]
20. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
Dhimolea E; Reichert JM
MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
